Millenium Pharmaceuticals Inc
Article Abstract:
The FDA recently validated Millennium Pharmaceuticals Inc.'s product to treat myeloma and Abbott Laboratories has aquired a stake in the compan y. The product, Velcade, should generate revenues for the company when commercialized and this issue thus carries wide appreciation potential out to 20060-2008.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2003
User Contributions:
Comment about this article or add new information about this topic:
Sepracor
Article Abstract:
Sepracor Inc.'s drug application for Estora was approved by the FDA and although the company has a large debt burden its topline should advanced in 2003 and 2004. Shares are risky ranking above average for Timeliness but to be avoided by long-term investment accounts.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2003
User Contributions:
Comment about this article or add new information about this topic: